Irritable Bowel Syndrome – Pipeline Review, H1 2013Global Markets DirectFebruary 28, 2013 145 Pages - SKU: GMD4986631 |
- Introduction
- Global Markets Direct Report Coverage
- Irritable Bowel Syndrome Overview
- Therapeutics Development
- An Overview of Pipeline Products for Irritable Bowel Syndrome
- Irritable Bowel Syndrome Therapeutics under Development by Companies
- Irritable Bowel Syndrome Therapeutics under Investigation by Universities/Institutes
- Late Stage Products
- Comparative Analysis
- Mid Clinical Stage Products
- Comparative Analysis
- Early Clinical Stage Products
- Comparative Analysis
- Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Irritable Bowel Syndrome Therapeutics – Products under Development by Companies
- Irritable Bowel Syndrome Therapeutics – Products under Investigation by Universities/Institutes
- Companies Involved in Irritable Bowel Syndrome Therapeutics Development
- AstraZeneca PLC
- Dainippon Sumitomo Pharma Co., Ltd.
- Albany Molecular Research, Inc.
- Astellas Pharma Inc.
- Dong-A Pharmaceutical Co., Ltd.
- Kureha Corporation
- Ono Pharmaceutical Co., Ltd.
- Menarini Group
- Shire Plc
- Pharmos Corporation
- Lexicon Pharmaceuticals, Inc.
- Yuhan Corporation
- ProMetic Life Sciences Inc.
- Probiomics Ltd.
- Alba Therapeutics Corporation
- Ironwood Pharmaceuticals, Inc.
- Respiratorius AB
- Tioga Pharmaceuticals, Inc.
- Targacept, Inc.
- Drais Pharmaceuticals, Inc.
- Synergy Pharmaceuticals, Inc.
- Napo Pharmaceuticals, Inc.
- Ferring Pharmaceuticals, Inc.
- Alfa Wassermann S.p.A
- MicroDose Therapeutx, Inc.
- RaQualia Pharma Inc.
- Irritable Bowel Syndrome – Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Drug Profiles
- ramosetron - Drug Profile
- ibodutant - Drug Profile
- crofelemer - Drug Profile
- LX-1031 - Drug Profile
- LIBS - Drug Profile
- M-0014 - Drug Profile
- linaclotide - Drug Profile
- linaclotide - Drug Profile
- rifaximin - Drug Profile
- asimadoline - Drug Profile
- asimadoline - Drug Profile
- M-0012 - Drug Profile
- MDT-006 - Drug Profile
- AST-120 - Drug Profile
- dextofisopam - Drug Profile
- plecanatide - Drug Profile
- dexloxiglumide - Drug Profile
- solabegron hydrochloride - Drug Profile
- larazotide acetate - Drug Profile
- TC-6499 - Drug Profile
- ALB-137391(a) - Drug Profile
- RQ-00202730 - Drug Profile
- elobixibat - Drug Profile
- PBI-1737 - Drug Profile
- eluxadoline - Drug Profile
- RQ-00310941 - Drug Profile
- DA-6886 - Drug Profile
- RDX-5791 - Drug Profile
- ONO-2952 - Drug Profile
- LX-1033 - Drug Profile
- ASP-7147 - Drug Profile
- YH-12852 - Drug Profile
- (Mosapride + Bacillus subtilis + Streptococcas feacium) - Drug Profile
- DSP-6952 - Drug Profile
- mexiletine hydrochloride - Drug Profile
- Irritable Bowel Syndrome Therapeutics – Drug Profile Updates
- Irritable Bowel Syndrome Therapeutics – Discontinued Products
- Irritable Bowel Syndrome Therapeutics - Dormant Products
- Irritable Bowel Syndrome – Product Development Milestones
- Featured News & Press Releases
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Number of Products Under Development for Irritable Bowel Syndrome, H1 2013
- Products under Development for Irritable Bowel Syndrome – Comparative Analysis, H1 2013
- Number of Products under Development by Companies, H1 2013
- Number of Products under Development by Companies, H1 2013 (Contd..1)
- Number of Products under Investigation by Universities/Institutes, H1 2013
- Comparative Analysis by Late Stage Development, H1 2013
- Comparative Analysis by Mid Clinical Stage Development, H1 2013
- Comparative Analysis by Early Clinical Stage Development, H1 2013
- Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2013
- Products under Development by Companies, H1 2013
- Products under Development by Companies, H1 2013 (Contd..1)
- Products under Investigation by Universities/Institutes, H1 2013
- AstraZeneca PLC, H1 2013
- Dainippon Sumitomo Pharma Co., Ltd., H1 2013
- Albany Molecular Research, Inc., H1 2013
- Astellas Pharma Inc., H1 2013
- Dong-A Pharmaceutical Co., Ltd., H1 2013
- Kureha Corporation, H1 2013
- Ono Pharmaceutical Co., Ltd., H1 2013
- Menarini Group, H1 2013
- Shire Plc, H1 2013
- Pharmos Corporation, H1 2013
- Lexicon Pharmaceuticals, Inc., H1 2013
- Yuhan Corporation, H1 2013
- ProMetic Life Sciences Inc., H1 2013
- Probiomics Ltd., H1 2013
- Alba Therapeutics Corporation, H1 2013
- Ironwood Pharmaceuticals, Inc., H1 2013
- Respiratorius AB, H1 2013
- Tioga Pharmaceuticals, Inc., H1 2013
- Targacept, Inc., H1 2013
- Drais Pharmaceuticals, Inc., H1 2013
- Synergy Pharmaceuticals, Inc., H1 2013
- Napo Pharmaceuticals, Inc., H1 2013
- Ferring Pharmaceuticals, Inc., H1 2013
- Alfa Wassermann S.p.A, H1 2013
- MicroDose Therapeutx, Inc., H1 2013
- RaQualia Pharma Inc., H1 2013
- Assessment by Monotherapy Products, H1 2013
- Assessment by Combination Products, H1 2013
- Assessment by Stage and Route of Administration, H1 2013
- Assessment by Stage and Molecule Type, H1 2013
- Irritable Bowel Syndrome Therapeutics – Drug Profile Updates
- Irritable Bowel Syndrome Therapeutics – Discontinued Products
- Irritable Bowel Syndrome Therapeutics – Dormant Products
- Irritable Bowel Syndrome Therapeutics – Dormant Products (Contd..1)
- Irritable Bowel Syndrome Therapeutics – Dormant Products (Contd..2)
- Irritable Bowel Syndrome Therapeutics – Dormant Products (Contd..3)
- List of Figures
- Number of Products under Development for Irritable Bowel Syndrome, H1 2013
- Products under Development for Irritable Bowel Syndrome – Comparative Analysis, H1 2013
- Products under Development by Companies, H1 2013
- Products under Investigation by Universities/Institutes, H1 2013
- Late Stage Products, H1 2013
- Mid Clinical Stage Products, H1 2013
- Early Clinical Stage Products, H1 2013
- Discovery and Pre-Clinical Stage Products, H1 2013
- Assessment by Monotherapy Products, H1 2013
- Assessment by Combination Products, H1 2013
- Assessment by Route of Administration, H1 2013
- Assessment by Stage and Route of Administration, H1 2013
- Assessment by Molecule Type, H1 2013
- Assessment by Stage and Molecule Type, H1 2013
Research assistance
We can help you find what you need. Call us or write us: Need help in your search?
US: 800.298.5699
Int'l: +1.240.747.3093
Related Markets
Gastrointestinal Reports